(R)-prolinol hydrochloride | 143767-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-prolinol hydrochloride
• 英文别名: (R)-2-Pyrrolidinemethanol Hydrochloride；[(2R)-pyrrolidin-2-yl]methanol;hydrochloride
• CAS: 143767-55-9
• 化学式: C₅H₁₁NO*ClH
• 分子量: 137.609
• InChiKey: FWXXCGIUQGFYIX-NUBCRITNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  (R)-prolinol hydrochloride 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 D-脯氨醇
  参考文献：
  名称：

  Application of Chiral Transfer Reagents to Improve Stereoselectivity and Yields in the Synthesis of the Antituberculosis Drug Bedaquiline

  摘要：

  DOI：

  10.1021/acs.oprd.3c00287

文献信息

• Structure guided design of a series of sphingosine kinase (SphK) inhibitors
  作者：Darin J. Gustin、Yihong Li、Matthew L. Brown、Xiaoshan Min、Mike J. Schmitt、Malgorzata Wanska、Xiaodong Wang、Richard Connors、Sheere Johnstone、Mario Cardozo、Alan C. Cheng、Shawn Jeffries、Brendon Franks、Shyun Li、Shanling Shen、Mariwil Wong、Holger Wesche、Guifen Xu、Timothy J. Carlson、Matthew Plant、Kurt Morgenstern、Karen Rex、Joanna Schmitt、Angela Coxon、Nigel Walker、Frank Kayser、Zhulun Wang

  DOI：10.1016/j.bmcl.2013.06.030

  日期：2013.8

  inhibition of both isoforms is likely required to block SphK dependent angiogenesis. A structure based approach was used to design and synthesize a series of SphK inhibitors resulting in the identification of the first potent inhibitors of both isoforms of human SphK. Additionally, to our knowledge, this series of inhibitors contains the only sufficiently potent inhibitors of murine SphK1 with suitable

  鞘氨醇-1-磷酸（S1P）信号在有丝分裂，细胞迁移和血管生成中起着至关重要的作用。鞘氨醇激酶（SphKs）催化鞘磷脂代谢中的关键步骤，从而导致S1P的产生。SphK有两种同工型，对SphK缺陷小鼠的观察表明，这两种同工型可以弥补彼此的损失。因此，可能需要抑制两种同工型才能阻断SphK依赖性血管生成。基于结构的方法用于设计和合成一系列SphK抑制剂，从而鉴定出人类SphK两种同工型的第一种有效抑制剂。此外，据我们所知，
• 丹参酮I衍生物及其制备方法和应用
  申请人：中国科学院上海药物研究所

  公开号：CN105622709A

  公开（公告）日：2016-06-01

  本发明涉及通式(I)所示丹参酮I衍生物，其中Z为OR1、NR2R3或X。本发明还涉及通式(I)所示丹参酮I衍生物的制备方法，以及通式(I)的丹参酮I衍生物或其药学上可接受的盐在制备药物、特别是抗肿瘤药物中的用途。
• BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076292A1

  公开（公告）日：2011-03-31

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；而B是与苯并噁唑环融合的吡唑基、咪唑基或三唑基环，可用于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。揭示了使用公式I中的化合物用于哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Benzoxazepin P13K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08242104B2

  公开（公告）日：2012-08-14

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；B是咪唑环、咪唑啉环或三唑啉环融合到苯并噁唑环上，用于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。还公开了使用公式I中化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Benzoxazepin PI3K inhibitor compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US08343955B2

  公开（公告）日：2013-01-01

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物及其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；B是嘧唑环、咪唑环或三唑环，融合到苯并噁唑环上，用于抑制脂质激酶，包括p110 alpha和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。